SIMCERE PHARMA (02096) has announced preliminary projections for the fiscal year ending December 31, 2025. Based on an initial review of the company's unaudited consolidated management accounts, the following performance is anticipated: The Group expects to report revenue between approximately RMB 7.7 billion and RMB 7.8 billion for the 2025 fiscal year. This represents an increase of roughly 16.0% to 17.6% compared to the revenue of about RMB 6.635 billion recorded for the fiscal year ended December 31, 2024.

Profit attributable to the company's equity shareholders is forecasted to be in the range of approximately RMB 1.3 billion to RMB 1.4 billion for the 2025 fiscal year. This signifies a substantial growth of about 80.1% to 93.9% over the restated profit attributable to equity shareholders of approximately RMB 722 million for the 2024 fiscal year.

Furthermore, the Group expects to achieve an adjusted profit attributable to equity shareholders of approximately RMB 1.25 billion to RMB 1.35 billion for the 2025 fiscal year. This would mark an increase of about 24.1% to 34.1% compared to the restated adjusted profit attributable to equity shareholders of roughly RMB 1.007 billion for the previous fiscal year.

The primary drivers behind the growth in these key financial metrics are attributed to increased revenue from innovative drugs, higher income from out-licensing agreements, and a net gain from the fair value change of the Group's investment portfolio.